FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 09/2024 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 09/2024”.

The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.

As of the end of September 2024 we identified the following current VC trends in the United States:

• Total Healthcare & Life Sciences funding reached EUR 27,796m
• Biotech/Pharma received 53% of the total investment volume (EUR 14,716m) with oncology being the leading indication (26%)
• In September Candid Therapeutics secured the highest transaction volume with EUR 334m, followed by ArsenalBio with EUR 294m and Egenesis with EUR 173m
• RA Capital Management (United States) is the most active investor (by deal volume in 2024), followed by ARCH Venture Partners (United States) and F-Prime Capital (United States)

To access the full report, please click here.